title: ÐÐ½ÑÐµÑÐ»ÐµÐ¹ÐºÐ¸Ð½Ñ Ð² ÐºÑÐ¾Ð²Ð¸ Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ¾Ð² Ñ Ð±Ð¾Ð»ÐµÐ·Ð½ÑÑ ÐÐ°ÑÐºÐ¸Ð½ÑÐ¾Ð½Ð°: Ð¼ÐµÑÐ°-Ð°Ð½Ð°Ð»Ð¸Ð· Ð´Ð°Ð½Ð½ÑÑ
title: Ð²ÑÐ¿ÑÑÐºÐ½Ð°Ñ ÐºÐ²Ð°Ð»Ð¸ÑÐ¸ÐºÐ°ÑÐ¸Ð¾Ð½Ð½Ð°Ñ ÑÐ°Ð±Ð¾ÑÐ° Ð±Ð°ÐºÐ°Ð»Ð°Ð²ÑÐ°
titleType: Subtitle
title: Interleukins in the blood of patients with Parkinson's disease: meta-analysis of data
Creators: name: ÐÐ°Ð½Ð°ÑÑÐ½, ÐÑÑÐµÐ¼
Publisher: name: Ð¡Ð°Ð½ÐºÑ-ÐÐµÑÐµÑÐ±ÑÑÐ³ÑÐºÐ¸Ð¹ Ð¿Ð¾Ð»Ð¸ÑÐµÑÐ½Ð¸ÑÐµÑÐºÐ¸Ð¹ ÑÐ½Ð¸Ð²ÐµÑÑÐ¸ÑÐµÑ ÐÐµÑÑÐ° ÐÐµÐ»Ð¸ÐºÐ¾Ð³Ð¾
Year: 2022
Subjects: Ð¸Ð½ÑÐµÑÐ»ÐµÐ¹ÐºÐ¸Ð½
ÑÐ¸ÑÐ¾ÐºÐ¸Ð½Ñ
Ð±Ð¾Ð»ÐµÐ·Ð½Ñ ÐÐ°ÑÐºÐ¸Ð½ÑÐ¾Ð½Ð°
Ð¼ÐµÑÐ°-Ð°Ð½Ð°Ð»Ð¸Ð·
interleukin
cytokines
Parkinsonâs disease
meta-analysis

description: ÐÐ¾Ð»ÐµÐ·Ð½Ñ ÐÐ°ÑÐºÐ¸Ð½ÑÐ¾Ð½Ð° (ÐÐ) ÑÐ²Ð»ÑÐµÑÑÑ Ð²ÑÐ¾ÑÑÐ¼ Ð¿Ð¾ ÑÐ°ÑÐ¿ÑÐ¾ÑÑÑÐ°Ð½ÐµÐ½Ð½Ð¾ÑÑÐ¸ Ð½ÐµÐ¹ÑÐ¾Ð´ÐµÐ³ÐµÐ½ÐµÑÐ°ÑÐ¸Ð²Ð½ÑÐ¼ Ð·Ð°Ð±Ð¾Ð»ÐµÐ²Ð°Ð½Ð¸ÐµÐ¼ Ð¿Ð¾ÑÐ»Ðµ Ð±Ð¾Ð»ÐµÐ·Ð½Ð¸ ÐÐ»ÑÑÐ³ÐµÐ¹Ð¼ÐµÑÐ°. ÐÑÐµ Ð±Ð¾Ð»ÑÑÐµÐµ Ð´Ð°Ð½Ð½ÑÑ ÑÐ²Ð¸Ð´ÐµÑÐµÐ»ÑÑÑÐ²ÑÐµÑ Ð¾ ÑÐ¾Ð¼, ÑÑÐ¾ Ð²Ð¾ÑÐ¿Ð°Ð»ÐµÐ½Ð¸Ðµ Ð¸Ð³ÑÐ°ÐµÑ Ð²Ð°Ð¶Ð½ÑÑ ÑÐ¾Ð»Ñ Ð² Ð¿Ð°ÑÐ¾Ð³ÐµÐ½ÐµÐ·Ðµ ÐÐ. ÐÐ½ÑÐµÑÐ»ÐµÐ¹ÐºÐ¸Ð½Ñ ÑÐ²Ð»ÑÑÑÑÑ ÐºÑÐ¸ÑÐ¸ÑÐµÑÐºÐ¸ Ð²Ð°Ð¶Ð½ÑÐ¼Ð¸ ÑÐ¸Ð³Ð½Ð°Ð»ÑÐ½ÑÐ¼Ð¸ Ð¼Ð¾Ð»ÐµÐºÑÐ»Ð°Ð¼Ð¸ Ð¸Ð¼Ð¼ÑÐ½Ð½Ð¾Ð¹ Ð°ÐºÑÐ¸Ð²Ð°ÑÐ¸Ð¸, ÐºÐ¾ÑÐ¾ÑÑÐµ Ð¾ÐºÐ°Ð·ÑÐ²Ð°ÑÑ Ð²Ð»Ð¸ÑÐ½Ð¸Ðµ Ð² Ð³Ð¾Ð»Ð¾Ð²Ð½Ð¾Ð¼ Ð¼Ð¾Ð·Ð³Ðµ Ð¸ Ð½Ð° Ð¿ÐµÑÐ¸ÑÐµÑÐ¸Ð¸. ÐÐ° Ð´Ð°Ð½Ð½ÑÐ¹ Ð¼Ð¾Ð¼ÐµÐ½Ñ Ð½ÐµÑ Ð¾Ð±ÑÐµÐ¿ÑÐ¸Ð½ÑÑÐ¾Ð¹ ÑÐ¾ÑÐºÐ¸ Ð·ÑÐµÐ½Ð¸Ñ Ð¾Ð± Ð°ÑÑÐ¾ÑÐ¸Ð°ÑÐ¸ÑÑ Ð¼ÐµÐ¶Ð´Ñ ÐºÐ¾Ð½ÑÐµÐ½ÑÑÐ°ÑÐ¸ÑÐ¼Ð¸ Ð¸Ð½ÑÐµÑÐ»ÐµÐ¹ÐºÐ¸Ð½Ð¾Ð² Ð² ÐºÑÐ¾Ð²Ð¸ Ð¸ ÐÐ. Ð¦ÐµÐ»ÑÑ Ð´Ð°Ð½Ð½Ð¾Ð³Ð¾ Ð¸ÑÑÐ»ÐµÐ´Ð¾Ð²Ð°Ð½Ð¸Ñ Ð±ÑÐ»Ð¾ Ð¿ÑÐ¾Ð²ÐµÐ´ÐµÐ½Ð¸Ðµ Ð¼ÐµÑÐ°-Ð°Ð½Ð°Ð»Ð¸Ð·Ð° Ð´Ð°Ð½Ð½ÑÑ Ð¾ ÐºÐ¾Ð½ÑÐµÐ½ÑÑÐ°ÑÐ¸Ð¸ Ð¸Ð½ÑÐµÑÐ»ÐµÐ¹ÐºÐ¸Ð½Ð¾Ð² Ð² ÐºÑÐ¾Ð²Ð¸ Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ¾Ð² Ñ Ð±Ð¾Ð»ÐµÐ·Ð½ÑÑ ÐÐ°ÑÐºÐ¸Ð½ÑÐ¾Ð½Ð°. ÐÐºÐ°Ð·Ð°Ð»Ð¾ÑÑ, ÑÑÐ¾ Ð²Ð¾ÑÐ¿Ð°Ð»Ð¸ÑÐµÐ»ÑÐ½ÑÐ¹ Ð¾ÑÐ²ÐµÑ Ð¿ÑÐ¸ ÑÐ°Ð·Ð²Ð¸ÑÐ¸Ð¸ ÐÐ ÑÐ¾Ð¿ÑÐ¾Ð²Ð¾Ð¶Ð´Ð°ÐµÑÑÑ ÑÐ²ÐµÐ»Ð¸ÑÐµÐ½Ð¸ÐµÐ¼ ÐºÐ¾Ð½ÑÐµÐ½ÑÑÐ°ÑÐ¸Ð¸ ÐÐ-1Î², ÐÐ-2, ÐÐ-6 Ð¸ ÐÐ-10 Ð² ÐºÑÐ¾Ð²Ð¸ Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ¾Ð² Ñ ÐÐ; Ð´Ð°Ð½Ð½ÑÐµ Ð¾ ÑÐ¾Ð´ÐµÑÐ¶Ð°Ð½Ð¸Ð¸ Ð² ÐºÑÐ¾Ð²Ð¸ Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ¾Ð² Ñ Ð±Ð¾Ð»ÐµÐ·Ð½ÑÑ ÐÐ°ÑÐºÐ¸Ð½ÑÐ¾Ð½Ð° Ð¸Ð½ÑÐµÑÐ»ÐµÐ¹ÐºÐ¸Ð½Ð° 2 Ð¸ Ð¸Ð½ÑÐµÑÐ»ÐµÐ¹ÐºÐ¸Ð½Ð° 6 ÑÐ²Ð»ÑÑÑÑÑ Ð²ÑÑÐ¾ÐºÐ¾ Ð³ÐµÑÐµÑÐ¾Ð³ÐµÐ½Ð½ÑÐ¼Ð¸, Ð¸Ð½ÑÐµÑÐ»ÐµÐ¹ÐºÐ¸Ð½Ð° 1Î² Ð¸ Ð¸Ð½ÑÐµÑÐ»ÐµÐ¹ÐºÐ¸Ð½Ð° 10 â ÑÐ¼ÐµÑÐµÐ½Ð½Ð¾ Ð³ÐµÑÐµÑÐ¾Ð³ÐµÐ½Ð½ÑÐ¼Ð¸, Ð° Ð¸Ð½ÑÐµÑÐ»ÐµÐ¹ÐºÐ¸Ð½Ð° 4 Ð¸ Ð¸Ð½ÑÐµÑÐ»ÐµÐ¹ÐºÐ¸Ð½Ð° 8 â Ð½Ð¸Ð·ÐºÐ¾ Ð³ÐµÑÐµÑÐ¾Ð³ÐµÐ½Ð½ÑÐ¼Ð¸. ÐÐµÑÐµÑÐ¾Ð³ÐµÐ½Ð½Ð¾ÑÑÑ Ð´Ð»Ñ Ð¸Ð½ÑÐµÑÐ»ÐµÐ¹ÐºÐ¸Ð½Ð°-6 ÑÐ½Ð¸Ð·Ð¸Ð»Ð°ÑÑ Ð½Ð° 28% Ð·Ð° ÑÑÐµÑ Ð°Ð½Ð°Ð»Ð¸Ð·Ð° Ð¿Ð¾Ð´Ð³ÑÑÐ¿Ð¿; Ð·Ð½Ð°ÑÐ¸Ð¼Ð¾ÑÑÑ Ð°ÑÑÐ¾ÑÐ¸Ð°ÑÐ¸Ð¸ Ð¼ÐµÐ¶Ð´Ñ Ð¿Ð¾Ð²ÑÑÐµÐ½Ð½ÑÐ¼Ð¸ ÑÑÐ¾Ð²Ð½ÑÐ¼Ð¸ Ð¸Ð½ÑÐµÑÐ»ÐµÐ¹ÐºÐ¸Ð½Ð°-6 Ð¸ Ð±Ð¾Ð»ÐµÐ·Ð½ÑÑ ÐÐ°ÑÐºÐ¸Ð½ÑÐ¾Ð½Ð° Ð´Ð»Ñ Ð³ÑÑÐ¿Ð¿Ñ Ð¼ÐµÑÐ¾Ð´Ð¾Ð², Ð¸ÑÐºÐ»ÑÑÐ°Ñ Ð¸Ð¼Ð¼ÑÐ½Ð¾ÑÐµÑÐ¼ÐµÐ½ÑÐ½ÑÐ¹ Ð°Ð½Ð°Ð»Ð¸Ð·, ÑÐ¾ÑÑÐ°Ð½Ð¸Ð»Ð°ÑÑ. ÐÑÐ»Ð¾ Ð¿Ð¾ÐºÐ°Ð·Ð°Ð½Ð¾, ÑÑÐ¾ Ð²Ð¾Ð·ÑÐ°ÑÑ Ð¾ÐºÐ°Ð·ÑÐ²Ð°ÐµÑ ÑÐ¼ÐµÑÐµÐ½Ð½Ð¾Ðµ Ð²Ð»Ð¸ÑÐ½Ð¸Ðµ Ð½Ð° ÑÐµÐ·ÑÐ»ÑÑÐ°ÑÑ Ð¼ÐµÑÐ°-Ð°Ð½Ð°Ð»Ð¸Ð·Ð°, Ð² ÑÐ¾ Ð²ÑÐµÐ¼Ñ ÐºÐ°Ðº Ð¿Ð¾Ð» Ð½Ðµ Ð¾ÐºÐ°Ð·ÑÐ²Ð°ÐµÑ Ð²Ð»Ð¸ÑÐ½Ð¸Ñ Ð½Ð° ÑÐµÐ·ÑÐ»ÑÑÐ°ÑÑ. ÐÐ½Ð°ÑÐ¸ÑÐµÐ»ÑÐ½ÑÐµ Ð°ÑÑÐ¾ÑÐ¸Ð°ÑÐ¸Ð¸ Ð² Ð´Ð°Ð½Ð½Ð¾Ð¼ Ð¼ÐµÑÐ°-Ð°Ð½Ð°Ð»Ð¸Ð·Ðµ Ð½Ðµ Ð²ÑÐ·Ð²Ð°Ð½Ñ Ð¿ÑÐµÐ´Ð²Ð·ÑÑÐ¾ÑÑÑÑ Ð¿ÑÐ±Ð»Ð¸ÐºÐ°ÑÐ¸Ð¹.
description: Parkinson's disease (PD) is the second most common neurodegenerative disease after Alzheimer's disease. Increasing evidence suggests that inflammation plays an important role in the pathogenesis of PD. Interleukins are critical signaling molecules of immune activation that have an effect in the brain and on the periphery. Nowdays, there is no generally accepted point of view about the associations between the concentrations of interleukins in the blood and BP. The purpose of this study was to conduct a meta-analysis of data on the concentration of interleukins in the blood of patients with Parkinson's disease. It turned out that the inflammatory response in the development of PD is accompanied by an increase in the concentration of IL-1Î², IL-2, IL-6 and IL-10 in the blood of patients with PD; data on the content of interleukin 2 and interleukin 6 in the blood of patients with Parkinson's disease are highly heterogeneous, interleukin 1Î² and interleukin 10 are moderately heterogeneous, and interleukin 4 and interleukin 8 are low heterogeneous. Heterogeneity for interleukin-6 decreased by 28% due to the analysis of subgroups; the significance of the association between elevated levels of interleukin-6 and Parkinson's disease for a group of methods, excluding enzyme immunoassay, remained. Age has been shown to have a moderate effect on the results of the meta-analysis, while gender has no effect on the results. Significant associations in this meta-analysis are not caused by publication bias.